Engineered Microorganisms as GLP-1-Oriented Living Therapeutics for Diabetes and Obesity: Mechanisms and Translational Challenges
International Journal of Molecular Sciences · 07.11.2026 · 27 (21) · 9977
DOI: 10.3390/ijms27219977 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.11.2026. Verfasst von Arthur A Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, 119334 Moscow, Russia. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Obesity, Diabetes Mellitus, Type 2, Microorganisms, Genetically-Modified. Die Arbeit nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Education and Science of the Russian Federation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for obesity and type 2 diabetes mellitus, but gastrointestinal barriers constrain oral delivery of peptide therapeutics. Genetically engineered microorganisms have been investigated as intestinal sources of GLP-1-related therapeutic molecules. These platforms produce GLP-1 or GLP-1-derived peptides, express modified GLP-1RAs or fusion proteins, or release effectors that stimulate endogenous GLP-1 secretion. Preclinical studies have reported improvements in glycemic measures and, in some models, reductions in body weight or weight gain. However, recombinant product expression and treatment-associated effects are more consistently demonstrated than exposure to intact biologically active products in vivo, receptor or pathway dependence, and the contribution of the engineered construct relative to the microbial chassis. Proteolysis, mucus interactions, restricted epithelial permeability, and receptor localization constrain access to intestinal and systemic targets. This review critically evaluates the preclinical evidence for GLP-1-oriented engineered microorganisms, with emphasis on intestinal target accessibility, local and systemic mechanisms, microbial chassis and genetic design, and the safety, manufacturing, and regulatory requirements for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, 119334 Moscow, Russia.
ORCID-Profile: Arthur A Lee, Victoria A Khotina, Dmitry A Kashirskikh
Förderung
- The Ministry of Education and Science of the Russian Federation
Zitieren
APA
Lee, A. A., Khotina, V. A., Klychkova, O. O., Novikova, V. S., Kashirskikh, D. A., & Gasanov, V. A. (2026). Engineered Microorganisms as GLP-1-Oriented Living Therapeutics for Diabetes and Obesity: Mechanisms and Translational Challenges. International Journal of Molecular Sciences, 27(21), 9977. https://doi.org/10.3390/ijms27219977
Vancouver
Lee AA, Khotina VA, Klychkova OO, Novikova VS, Kashirskikh DA, Gasanov VA. Engineered Microorganisms as GLP-1-Oriented Living Therapeutics for Diabetes and Obesity: Mechanisms and Translational Challenges. International Journal of Molecular Sciences. 2026;27(21):9977. doi:10.3390/ijms27219977
BibTeX
@article{Lee2026,
author = {Lee, Arthur A and Khotina, Victoria A and Klychkova, Olesya O and Novikova, Vitalia S and Kashirskikh, Dmitry A and Gasanov, Vagif A},
title = {Engineered Microorganisms as GLP-1-Oriented Living Therapeutics for Diabetes and Obesity: Mechanisms and Translational Challenges},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9977},
doi = {10.3390/ijms27219977}
}
EUVIMED